AI-powered biotechnology company Enveda Biosciences has secured USD 55 million in a Series B2 funding round; Series B-1 in April 2023 raised USD 51 million. The round saw participation from new investors including Premji Invest, Lingotto Investment Fund, Microsoft, and The Nature Conservancy, as well as existing investors like Kinnevik and True Ventures.
The company intends to use the procured funds to develop its novel AI-powered platform further and to commence Phase I clinical trials for its three lead programs in late 2024 and early 2025.
The Colorado-based company develops novel therapeutics based on plants and natural chemistry to treat various diseases, including Wilson’s Disease, NASH, and Parkinson’s disease. Enveda’s proprietary platform, powered by machine learning and metabolomics, acts as a search engine to discover and identify novel drug candidates.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.